2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P1271A
    Catestatin TFA 99.07%
    Catestatin TFA is a 21-amino acid residue, cationic and hydrophobic peptide. Catestatin TFA is an endogenous peptide that regulates cardiac function and blood pressure. Catestatin TFA is a non-competitive nicotinic antagonist acting through nicotinic acetylcholine receptors (nAChRs) to inhibit catecholamine release.
    Catestatin TFA
  • HY-P1949A
    Cyclic MKEY TFA 98.47%
    Cyclic MKEY TFA is a synthetic cyclic peptide inhibitor of CXCL4-CCL5 heterodimer formation, which protects against atherosclerosis and aortic aneurysm formation by mediating inflammation. Cyclic MKEY TFA also protects against stroke-induced brain injury in mice.
    Cyclic MKEY TFA
  • HY-P2222A
    DX600 TFA 99.20%
    DX600 TFA is a selective ACE2 specific inhibitor (KD: 1.3 nM), and does not cross-react with ACE. DX600 TFA exacerbates diabetes-induced cardiovascular dysfunction and the increase in cardiac and renal NOX activity.
    DX600 TFA
  • HY-P2276A
    Pep2-8 TFA 98.78%
    Pep2-8 is a peptide which has enhanced the antagonistic activity of proprotein convertase subtilin/ kexin 9 type (PCSK9).
    Pep2-8 TFA
  • HY-P99905
    Efdamrofusp alfa 2375661-82-6 99.89%
    Efdamrofusp alfa is a bispecific fusion protein. Efdamrofusp alfa is capable of neutralizing both VEGF isoforms and C3b/C4b. Efdamrofusp alfa can be used for the research of neovascular age-related macular degeneration (nAMD) and other complement-related ocular conditions.
    Efdamrofusp alfa
  • HY-U00186
    K134 189362-06-9 99.84%
    K134 is a phosphodiesterase 3 (PDE3) inhibitor. The IC50s of K134 toward PDE3A, PDE3B, PDE5, PDE2 and PDE4 are 0.1, 0.28, 12.1, >300 and >300 µM, respectively.
    K134
  • HY-113147B
    L-Palmitoylcarnitine TFA 98.0%
    L-Palmitoylcarnitine TFA, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine TFA inhibits KATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2.
    L-Palmitoylcarnitine TFA
  • HY-14664AS
    Fluvastatin-d6 sodium 98.06%
    Fluvastatin-d6 (sodium) is deuterium labeled Fluvastatin sodium. Fluvastatin sodium (XU 62320) is a first fully synthetic, competitive HMG-CoA reductase inhibitor with an IC50 of 8 nM.
    Fluvastatin-d6 sodium
  • HY-171978A
    LM-189 free base 99.45%
    LM-189 free base, a G protein alpha subunit I (Gαi)-biased agonist, is a Gαi-biased ligand of β2-adrenergic receptor (β2AR). LM-189 free base stabilizes a distinct conformation in TM6 and increases the dynamics of ICL2. LM-189 free base can be used to develop the Gαi-biased β2AR agonists.
    LM-189 free base
  • HY-B0309S2
    Felodipine-d3 1219795-30-8 99.78%
    Felodipine-d3 is the deuterium labeled Felodipine. Felodipine, a dihydropyridine, is a potent, vasoselective calcium channel antagonist. Felodipine lowers blood pressure (BP) by selective action on vascular smooth muscle, especially in the resistance vessels. Felodipine, an anti-hypertensive agent, induces autophagy. Felodipine can cross the blood-brain barrier.
    Felodipine-d3
  • HY-P10709A
    CREKA peptide acetate 98.07%
    CREKA peptide acetate is a short peptide sequence, belonging to self-assembling peptides (SAPs), which can self-assemble into functional nanostructures, typically nanofibers, under physiological conditions. CREKA peptide acetate can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity.
    CREKA peptide acetate
  • HY-W002314
    2-Bromo-4'-hydroxyacetophenone 2491-38-5 98.59%
    2-Bromo-4'-hydroxyacetophenone is a PTP1B inhibitor with a Ki value of 42 μM. 2-Bromo-4'-hydroxyacetophenone is also an intermediate. 2-Bromo-4'-hydroxyacetophenone can be used in the synthesis of LXRα/β antagonists. 2-Bromo-4'-hydroxyacetophenone can be used in research on hematological diseases.
    2-Bromo-4'-hydroxyacetophenone
  • HY-W010710
    IPrAuCl 852445-83-1 ≥98.0%
    IPrAuCl (compound 3) is a gold compound. IPrAuCl inhibits sarcoplasmic reticulum Ca2+-ATPase (IC50=16.3 µM).
    IPrAuCl
  • HY-W015881
    Dimebutic acid 595-37-9 99.85%
    Dimebutic acid is an orally active short-chain fatty acid. Dimebutic acid stimulates fetal globin production and alters the balance of Bcl family proteins. Dimebutic acid prolongs red blood cell survival. Dimebutic acid exhibits toxicity in rats. Dimebutic acid can be used in the study of β-thalassemia and sickle cell disease.
    Dimebutic acid
  • HY-W016644
    (S)-1-Benzylpyrrolidin-3-ol 101385-90-4 99.90%
    (S)-1-Benzylpyrrolidin-3-ol (Compound 14) can be used to synthesis impurities of the anti-hypertensive agent Barnidipine hydrochloride (HY-107322).
    (S)-1-Benzylpyrrolidin-3-ol
  • HY-W019726
    Dehydro Nifedipine 67035-22-7 99.84%
    Dehydro nifedipine (BAY-b 4759) is a metabolite of Nifedipine (HY-B0284). Nifedipine (BAY-a-1040) is a potent calcium channel blocker and an agent of choice for cardiac insufficiencies.
    Dehydro Nifedipine
  • HY-W021162
    Guanylate cyclase-IN-1 1361569-23-4 ≥99.0%
    Guanylate cyclase-IN-1 (Example 46) is a guanylate cyclase inhibitor that can be used for cardiovascular diseases research.
    Guanylate cyclase-IN-1
  • HY-W062836
    BAY 41-8543 256498-66-5 99.94%
    BAY 41-8543 is an orally active, nitric oxide (NO)-independent stimulator of soluble guanylyl cyclase (sGC). BAY 41-8543 has vasodilator activity in the pulmonary and systemic vascular beds in the rat. BAY 41-8543 has antiplatelet effects and has the potential for cardiovascular diseases research.
    BAY 41-8543
  • HY-W091734
    Methyl 4-iodo-L-phenylalaninate hydrochloride 158686-46-5
    Methyl 4-iodo-L-phenylalaninate hydrochloride is a Phenylalaninate derivative. Methyl 4-iodo-L-phenylalaninate hydrochloride can be used for the preparation of factor XI modulators used in the research of thrombotic and thromboembolic. Methyl 4-iodo-L-phenylalaninate hydrochloride can also be used for the synthesis of compounds for the research of amyloid-related diseases, such as Alzheimer’s disease.
    Methyl 4-iodo-L-phenylalaninate hydrochloride
  • HY-W127841
    Citric acid-2,4-13C2 121633-50-9 98.00%
    Citric acid-2,4-13C2 is the 13C-labeled Citric acid (HY-N1428). Citric acid is a natural preservative and food tartness enhancer. Citric acid induces apoptosis and cell cycle arrest at G2/M phase and S phase in HaCaT cells. Citric acid cause oxidative damage of the liver by means of the decrease of antioxidative enzyme activities. Citric acid is also an acidulant, emulsifier, sequestrant and buffering agent widely used across many industries.
    Citric acid-2,4-13C2
Cat. No. Product Name / Synonyms Application Reactivity